United States v. Arthrex, Inc.

Background

Arthrex, a medical‑device company, held a patent on a surgical device. Competitors Smith & Nephew asked the Patent Trial and Appeal Board (PTAB) to reexamine the patent through inter partes review, a process where agency judges reconsider issued patents. A three‑judge PTAB panel found Arthrex’s patent invalid, and Arthrex appealed, arguing the agency judges were not constitutionally appointed because they exercise final executive authority.

Reasoning

The Court asked whether Administrative Patent Judges (APJs) who decide inter partes reviews are properly appointed and accountable. It concluded that because APJs issue final decisions that bind the Executive Branch and are insulated from direct review by a President‑nominated, Senate‑confirmed officer, their unreviewable authority conflicts with the Appointments Clause. To fix that, the Court read the statute so the PTO Director may review and issue final Board decisions, restoring political accountability.

Real world impact

The ruling means the Patent Office Director can now review final PTAB decisions, shifting responsibility to an official nominated by the President and confirmed by the Senate. That change affects companies and inventors involved in post‑grant patent challenges and could alter outcomes in many ongoing and future reviews. The Court vacated the Federal Circuit ruling and remanded the case for the Director to decide whether to rehear the Arthrex petition; that review could change the result.

Dissents or concurrances

Justices were sharply divided. Chief Justice Roberts’s opinion (Parts I–II) led the judgment; Justices Gorsuch, Breyer, and Thomas wrote separate opinions that partly agreed or dissented about the remedy and the underlying doctrine. Opinions disagreed on whether APJs are principal officers, whether Congress’s structure was permissible, and whether the proper fix is allowing Director review or other remedies.